Merck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
January 27 2022 - 6:46AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Thursday said the European Commission
approved expanded use of its blockbuster cancer drug Keytruda as
monotherapy for the adjuvant treatment of certain renal cell
carcinoma patients following surgery.
The Kenilworth, N.J., drugmaker said the approval covers adults
with renal cell carcinoma, the most common type of kidney cancer,
who are at increased risk of recurrence following nephrectomy, or
following nephrectomy and resection of metastatic lesions.
Merck said the approval is based on results from a Phase 3 study
in which Keytruda showed a statistically significant improvement in
disease-free survival, reducing the risk of disease recurrence or
death by 32% compared with placebo.
Keytruda, a cancer drug that harnesses a patient's immune system
to fight tumors, is approved in dozens of indications around the
world.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 27, 2022 07:31 ET (12:31 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024